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It  was  demonstrated  in  a  preceding  study  from  these  laboratories  that 
patients  with  the  genetic  liver disease  acute  intermittent  porphyria  (AIP) 1 
display a significant defect in the reductive transformation of prototy~)e steroid 
hormones  such  as testosterone and dehydroisoandrosterone (1). This defect is 
manifest  by the marked preferential metabolism of these hormones  along the 
5~-pathway--the pathway through which endogenous steroids having a potent 
ability  to  induce  the  mitochondrial  enzyme  &aminolevulinate  synthetase 
(ALAS)  are  generated  (1-3).  ALAS  controls  the  rate-limiting  step  in  por- 
phyrin-heme synthesis (4) and has been found  at high levels of activity in the 
livers of AIP patients (5). This excessive activity of hepatic ALAS accounts for 
the  overproduction  of porphyrin precursors  which  characterizes  this  genetic 
disorder (6-8). 
Reduction of the double bond at the A : B ring junction of neutral steroid hormones 
is catalyzed in the liver by two classes of enzymes: steroid A4-5a-reductases localized 
in  the membranes of  the endoplasmic reticulum and steroid A4-5fl-reductases found 
in  the  cytosol.  The  preferential metabolism  of  testosterone and  dehydroisoandro- 
sterone along the 5fl-pathway in AIP could therefore be due to a  decrease in the ac- 
tivity of the 5c~-reductase for these hormones, an increase in the activity of the 5fl- 
reductase, or both. To examine the enzymatic basis for the abnormal steroid hormone 
metabolism in AIP patients further, we have studied the metabolic disposition in them 
of  tracer  doses  of  the  adrenocortical  hormone,  l l~-hydroxyandrostenedione  (11- 
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1  Abbreviations used in  this  paper: AIP,  acute intermittent porphyria; ALAS, &amino- 
levulinate synthetase; A4-30H, a mixture of A4-androstene  17-ketosteroid  metabolites of 11- 
OHAD containing 3o~- or 3~-hydroxy, and  llfl-hydroxy or  ll-keto  substituents; ll=OE, 
5fl-androstane-3o~-hydroxy-ll,17-dione;  ll-OHA,  5a-androstane-3a-ll/3-dihydroxy-17-one; 
ll-OHAD,  A4-androstene-llfl-hydroxy-3,17-dione; ll-OHE,  5/3-androstane-3o~-ll/3-dihy- 
droxy-17-one;  PCT, porphyria cutanea tarda; URO-S, uroporphyrinogen  synthetase. 
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OHAD). This C-19 steroid has an oxygenated subsfituent  at the C-11  position that 
greatly hinders its biotransformation along the 5/3-pathway  (9) ; thus the metabolites 
formed from the hormone in man are predominantly of the 5a type. Examination of its 
metabolic fate in AIP patients affords, therefore, an extremely sensitive test of whether 
steroid A*-5a-reductase activity is normal or depressed in such individuals. 
The results of the present study indicate that AIP patients have a  markedly 
decreased  ability to effect the reductive transformation  of 11-OHAD along the 
5a-pathway,  as compared with normal subjects. The extent of this impairment 
of steroid 5a-reductase  activity is sufficient to explain the compensatory diver- 
sion  of  hormones  such  as  testosterone  and  dehydroisoandrosterone,  towards 
metabolism via the 5/3-pathway  in this disease  (1).  To establish  the specificity 
of this enzymatic deficiency in AIP similar studies were carried out in patients 
with the acquired form of hepatic porphyria,  porphyria  cutanea  tarda  (PCT). 
In  this  disorder,  normal  levels  of  activity of  the  steroid  A4-Sa-reductase  for 
l l-OHAD  were  demonstrated. 
Materials and Methods 
A  total  of  nine  normal  individuals, seven AIP patients,  and  three  PCT patients  were 
studied. All seven of the AIP patients belonged to the group A category defined in our previous 
report  (1)  in which the disorder though clinically manifest was  symptomatically mild; all 
patients also had abnormally low levels of activity of uroporphyrinogen synthetase  (URO-S) 
(10) in erythrocytes as determined by the method of Granick et al. (11). The normal subjects 
were age and sex matched with the AIP patients.  All studies were carried out on the wards 
of The Rockefeller University Clinical Research Center. 
Steroid Studies.--Isotopically  labeled  [4-14C or  1,23H]ll/3-hydroxyandrostenedione  (ll- 
OHAD), whose structure is shown in Fig. 1, was prepared by bismuthate oxidation of [4-14C]  - 
cortisol or [1, 23H]cortisol (12). Crude ll-OHAD was purified by paper chromatography and 
shown by  radioisotopic dilution  with carrier  ll-OHAD to have a  purity greater than  98%. 
1-10  /zl of the purified steroid [4-14C or 1,2-~H] was dissolved in a small volume of alcohol, 
diluted with approximately 100 ml of 5% glucose, and a weighed amount of this solution then 
administered  intravenously  to  the  subjects  over  15-20  rain  as  previously described  (13). 
Complete urine collections, determined from the constancy of the creatinine content, were 
made for 2 days after intravenous injection of the compound.  Urease and phosphate buffer 
were added in most cases to remove urea (13). The 2-day collections were combined and en- 
zymic and acid hydrolysis of the steroid conjugates was carried out by hydrolytic, extraction, 
and chromatographic  methods reported in detail elsewhere  (13). 
Two major extracts containing the glucuronidated metabolites of 11-OHAD were prepared 
by extensive hydrolysis with/3-glucuronidase (Ketodase  It) ; the numbers shown in Table I for 
percent  radioactivity of  glucuronide  extracts  represent  the combined  sum  of the recovery 
values for  these  two  glucuronide  extracts, 
The principal  metabolite of  ll-OHAD in  man  is the  5c~-steroid  ll-OHA  (Fig.  1).  Re- 
chromatography as well as reverse isotope dilution with carrier ll-OHA established that the 
radioactive peak  identified as containing this metabolite after appropriate chromatography 
was, in fact, substantially all authentic  ll-OHA. 
Additional  ll-OHA-containing conjugates  were  still present  in  the  urine  treated  with 
/3-glucuronidase  and  extensively extracted since subsequent  hot acid hydrolysis resulted in 
the liberation of the dehydration product of this metabolite, Ag(n)-androsterone. The recovery 
of this radioactive steroid, in terms of percent counts, after such hot acid treatment of urine 756  STUDIES IN  PORPHYRIA. II 
0  0 
0  f  HO" 
II-OHE  H~  II-OHA 
0 
/  II-OHAD  0  0 
HO' "~  H  O  ~'~~] 
II=OE  A  4 -30H 
FIG. I.  Structures of  llfl-hydroxy-A4-androstenedione (I1-OHAD)  and its metabolites. 
The abbreviations used are defined in footnote 1. The principal metabolite of ll-OHAD is 
the 5a-compound, I1-OHA shown in the upper right. The 5fl-steroids shown at the left repre- 
sent only minor transformation products of 11-OHAD. The C-3 hydroxyl of Aa-30H is de- 
signated (-]-]-[-]-]-]-)  to indicate a mixture of 30e- and 3/~-hydroxy compounds. 
is shown as the number under "acid extract" in Table I; and the specific amount of isolated 
Ag(n)-androsterone  found is included with the total amount found  of its precursor ll-OHA 
in Table II. Reverse isotope dilution analysis showed that the radioactive peaks migrating as 
the 5fl-steroids 11-OHE and 1  I=OE (Fig. 1) contained in addition to the authentic compounds, 
acid labile ring A unsaturated components  (i.e. ~4-3 hydroxylated steroids [Fig. 1]) similar to 
those excreted by myxedematous patients (13). The results of these isolation procedures are 
summarized  in the data shown in Table II; in this table, acid labile steroids are designated 
"A4-30H '' compounds. All samples were counted in a Packard 3320 scintillation  counter (Pack- 
ard Instrument Co., Inc., Downers Grove, IlL) using Diatol as the scintiIlant. 
RESULTS 
Table I  summarizes the mean  values for urinary excretion of radioactivity 
after  administration  of  labeled  ll-OHAD  to  normal  individuals  and  to  the 
porphyric patients, and the amount of radioactivity recovered in the form of the 
combined  "glucuronide  extracts"  and  the  "acid  extract"  of urine  from  each 
group of subjects. The excretion of labeled steroids was rapid and recovery of 
administered isotope was  similar and nearly quantitative in the three groups 
of individuals studied. The  pattern of metabolites produced from  ll-OHAD 
in the AIP patients, however, was considerably different from the normal sub- 
jects, as show in Table II. In the AIP patients there was a markedly decreased 
formation of the principal 5a-metabolite, ll-OHA, formed from  ll-OHAD  as 
compared with normals.  This  decreased formation of 5a-metabolite was  not 
compensated  for  by  an  enhanced  production  of  5fl-steroids  (i.e.  ll-OHE 
Table  II);  rather  there  was  a  very large increase in  output  of  steroids  (i.e. 
A4-3OH, Table II) in which the C 4-5 double bond was chemically unaltered. The BRADLOW,  GILLETTE,  GALLAGHER~ AND  KAPPAS  757 
TABLE  I 
Urinary Excretion and Hydrolysis of Metabolites of 14C-Labeled 11-OHAD* 
Subjects  (No.)  Urine  Glucuronide  Acid extracts  extracts 
Normals  (9)  93  58  19 
AIP  (7)  81  54  15 
PCT  (3)  92  59  22 
* Mean values for each group, expressed as percent of the administered radioactivity. 
TABLE  II 
Metabolism of XaC-Labded 11-OHAD in Normal Subjects and Porphyric Patients* 
Subjects  (No.) 
Metabolites formed 
ll-OHA  11~-----OE  A4-3OH 
Normals  (9)  63  12  1 
(55-71)  (7-16)  (0-2) 
AlP  (7)  33  12  33 
(26-38)  (4-19)  (10-58) 
PCT  (3)  52  6  10 
(35-61)  (4-9)  (8-14) 
Includes small amounts of the related 5/3-metabolite, ll-OHE. 
* Mean and range of values for each group expressed as percent radioactivity of the total 
neutral extracts. 
A4-30H includes a mixture of 3or- and 3/3-OH A4-metabolites of 11-OHAD. 
PCT  patients  (Table  II)  produced  normal  amounts  of  the  5a-metabolite, 
ll-OHA. The slightly increased output of ring A unsaturated steroids in these 
patients may result from a diversion of the small fraction of ll-OHAD, which 
is normally metabolized via the  5/3-pathway,  since the  amounts of  ll-OHE 
formed by PCT patients were slightly lower than those produced by the con- 
trol group. 
Fig.  2 depicts the individual values for percent 5a-metabolite formed from 
ll-OHAD in each of the AIP and normal subjects. The mean value for metab- 
olism of  ll-OHAD  along  the  5a-pathway in  the AIP patients  was  43%  or 
approximately one-half the mean value for controls, with  the  range in AIP 
patients extending from 34 to 70 % below the average value for 5a-metabolism 
in normals.  The mean value for percent 5a-metabolism of ll-OHAD  by the 
three PCT patients was slightly lower than the mean for normals (Table II) 
but the difference was not statistically significant and the specific values for 
these patients are not depicted in Fig. 2. 
DISCUSSION 
The data reported here establish that patients with AIP have a major de- 
ficiency in  activity  of  the  hormone-metabolizing  enzyme(s),  steroid-A4-5~- 758  STUDIES  IN  PORPHYRIA.  II 
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FIG. 2. Percent  5a-metabolism  of 11-OHAD in nine normal  subjects and  seven AIP pa- 
tients.  This pathway for the reductive  metabolism of steroid hormones is impaired in AIP 
subjects in whom the disease has become clinically expressed. 
reductase. This deficiency was demonstrated in all seven of the patients studied, 
and ranged in degree from 34 to 70 % less than the mean 5o~-reductase activity 
characterizing  normal  subjects.  The  5a-reductase  deficiency  was  defined  in 
terms of the adrenal hormone ll-OHAD as substrate for the enzyme; but it is 
reasonable  to  assume  that  the  deficient  5o~-metabolism  of other  steroid  hor- 
mones,  which  we  demonstrated  earlier  in  AIP  (1),  results  from  comparable 
enzymic abnormalities.  The ability of triiodothyronine to normalize the defect 
in  5o~-metabolism  of steroids  such  as  testosterone  in  AIP  (14)  supports  this 
view since thyroid hormone is a potent inducer of 5a-reductase activity in the 
liver.  There presumably is some degree of substrate  specificity for steroid 5oz- 
reductases but this question has not been examined in man; in any event, the 
impaired  5o~-metabolism  of  ll-OHAD,  testosterone,  and  dehydroisoandros- 
terone demonstrated  in this  and  earlier  studies  (1)  indicates  that  as a  class, BRADLOW,  GILLETTE,  GALLAGHER, AND  KAPPAS  759 
these  endoplasmic reticulum-bound  enzymes are clearly deficient in  activity 
in AIP patients as compared with normal subjects. Whether the deficiency is 
attributable  to direct defects in  the  enzyme(s) itself or in its synthesis and 
metabolism, to limitations on the availability of cofactors, or results from the 
presence of inhibitors of 5a-reductase in AIP patients,  etc., is not presently 
known. The assumption  that  the defect in 5a-reductase  activity shown here 
primarily  reflects  deficient  liver  enzyme  activity  is,  however,  undoubtedly 
valid.  Hepatic  extraction of  circulating  steroids  is  an  extremely rapid  and 
efficient process; and it is well known that intravenously administered tracer 
doses  of  steroid  hormones  undergo  metabolism  almost  exclusively in  liver 
cells in man. The possibility that other tissues of AIP patients may also display 
deficient  5a-reduction  of  hormones  should  nevertheless  be  explored  since 
identification of this steroid metabolic defect by less complex and costly means 
than those required for these studies would be useful. 
It should be noted that these data, while clearly defining a major deficiency 
of steroid-5a-reductase activity in AIP, do not completely exclude the existence 
of a concurrent elevation in activity of steroid-5/3-reductase in this disease. The 
AIP  patients  showed  no  increased  production  of  the  5/3-metabolites  of  ll- 
OHAD  in this study. However, the limited formation of such  metabolites in 
normal  subjects reflects the steric restriction imposed by the  C-11  hydroxyl 
substituent of ll-OHAD  on its 5/3-reductase; this enzymatic constraint  could 
also preclude a compensatory diversion of 11-OHAD metabolism from the 5a- to 
the 5/3-pathway in the AIP patients studied. Steroid hormones such as testos- 
terone and dehydroisoandrosterone, which lack a  C-11 substituent, present no 
steric restriction to the 5/~-reductase; and the 5/3-pathway thus remains acces- 
sible, as shown previously (1) for the reductive transformation of that fraction 
of such hormones that cannot otherwise be metabolized to 5o~-derivatives.  The 
extent to which shunting of hormones from the 5a- to the 5/3-reductase can take 
place in human  liver without requiring an increase in the specific activity of 
the  latter  enzyme  is  not  known.  Thus  while  the  deficiency in  steroid-5a- 
reductase  activity demonstrated here probably accounts entirely for the im- 
paired hormone metabolism seen in AIP patients, a reciprocal increase in 5/3- 
reductase activity cannot be completely ruled out. 
The formation of A4-30H metabolites in substantial quantity in AlP patients 
is  a  phenomenon that  we have previously observed only in  myxedematous 
subjects (13). It is of interest that this metabolic pattern was characteristic only 
of the biotransformation of 11-OHAD in the AIP subjects; studies with testos- 
terone in this disease as in myxedema (15) showed no excess production of ring 
A unsaturated metabolites. Another unusual feature of ll-OHAD metabolism 
in AIP is the occurrence of A4-30H  C-11-ketone metabolites; these were not 
previously observed with myxedematous patients who tend rather to have a 
relative  increase  in  C-11  hydroxyl over  C-11-ketonic  derivatives.  Indeed  a 
relative increase in  C-11-ketonic rnetabolites is  a  characteristic not of hypo- 760  STUDIES  IN  PORPHYRIA.  II 
thyroid,  but  of hyperthyroid,  individuals.  These findings  are consistent with 
earlier observations that indicate that the relative foimation of 5~- and A4-30H 
steroid metabolites is dependent on the effect of the C-11  substituent  on 5B- 
reductase activity (9). 
The AIP  subjects  described  in  this  report  were  all patients  in  whom  the 
disease, though only mildly active at the time of study, was nevertheless well 
defined on the basis of the usual  symptomatic and biochemical criteria (6-8). 
The 5o~-reductase deficiency demonstrated  here  thus  may typify only  those 
individuals whose gene defect for AIP has become clinically expressed. It is not 
known whether subjects in whom the AIP trait has remained completely latent, 
i.e. has never become clinically manifest, display a  similar enzyme deficiency. 
Such  subjects presumably comprise those individuals identified as having the 
trait  by low levels of erythrocyte URO-S  activity,  but  who have never had 
symptoms or evidence of increased excretion of porphyrin precursors? 
It is also not clear to what extent the deficient 5o~-reductase activity in AIP 
reflects the relative influence of genetic and extragenetic determinants on this 
enzyme  activity.  We  have previously  demonstrated  the  existence  of  major 
genetic influences on steroid hormone metabolism in man (16), and there may be 
significant heritable determinants of the patterns of 5o~- and 5~-metabolism of 
steroids in AIP patients as well.  Extragenetic factors, such as chemicals, hor- 
mones, etc., also affect the patterns of steroid metabolism in humans (17-19), 
and  recent  studies  from these laboratories have shown  that  porphyrinogenic 
drugs  can,  in  normal individuals,  depress 5a-reductase  activity and increase 
5B/5o~ metabolite ratios in a manner analogous to that found in untreated AIP 
patients (17). 
The possible relation of the 5a-reductase deficiency to the transformation of 
AIP from a latent to an active disorder at puberty merits particular considera- 
tion.  It is well  established  that  this inherited  disorder rarely manifests itself 
clinically before puberty. However, as Sassa et al. have shown (20, footnote 2), 
the erythrocyte URO-S defect that characterizes all subjects carrying the gene 
abnormality for AIP can be identified in children as young as 5 mo of age. The 
URO-S defect is thus not sufficient in itself to evoke clinical expression of AIP 
and additional biochemical or metabolic factors must underlie the transition of 
this disorder from the latent to the active state. 
In  this  regard  the  reductive  biotransformation  of  steroids  in  prepubertal 
children is known to preferentially favor the 5o~-pathway (21-23) ; this pattern 
changes near puberty, with a shift towards greater metabolism of hormones via 
the  5B-pathway,  taking  place  with  increasing  age  (24).  This  change  in  the 
pattern of steroid metabolism, together with the dramatic increase in synthesis 
of hormones and precursors that occurs at puberty, may be critical in determin- 
ing  clinical  expression of the latent gene defect for AIP in many affected in- 
dividuals. 
2 Sassa, S., S. Granick, D. R. Bickers, and A. Kappas. 1973. Manuscript in preparation. BRADLOW, GILLETTE, GALLAGHER~ AND  KAPPAS  761 
SUMMARY 
Patients with the genetic liver disease,  acute intermittent porphyria (AIP), 
have a defect in the reductive transformation of steroid hormones that is mani- 
fest by the disproportionate generation of 5~-steroid metabolites from precursor 
hormones.  5/~-steroid  metabolites  were  earlier  shown  to  be potent  inducers 
experimentally  of  ~-aminolevulinate  synthetase  (ALAS),  the  initochondrial 
enzyme that is rate-limiting in porphyrin synthesis, and that is found at high 
levels of activity in the livers of AIP patients. 
In this report, the basis for the defective steroid metabolism in AIP has been 
shown,  through  studies  with  the  1*C-labeled  adrenal  hormone  ll/~-hydroxy- 
A*-androstenedione,  to  reside  in  a  substantial  deficiency  of  hepatic  steroid 
A4-5a-reductase activity. This enzymic deficiency was found in all seven AIP 
patients  studied,  and ranged from 34%  to as much as 70%  below the mean 
enzyme activity characterizing normal subjects. 
The  functional  consequence  of  the  low  levels  of  5a-reductase  activity  in 
AIP is to divert the reductive transformation of certain natural hormones from 
the  5a-  to  the  5/~-pathway; the latter is  the metabolic route  through  which 
endogenous  steroids  having  the  potential  for  inducing  hepatic  ALAS  are 
generated.  It is not presently known whether  the  5a-reductase  deficiency in 
AIP is acquired in some fashion or whether it has partial genetic determinants. 
It seems probable, however, that this enzymatic abnormality, coupled with the 
dramatic increase in hormone synthesis that occurs at puberty, may be of major 
importance in determining clinical expression of the  latent gene defect for AIP 
in many individuals. The 5a-reductases for steroid hormones are known to be 
localized in the endoplasmic reticulum of hepatic cells and the present findings 
in AIP thus represent the first demonstration that an enzymic component of 
these membranous structures is functionally abnormal in this hereditary liver 
disease. 
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